Nicole Wilson
Family · Mansfield, OHNPI 1982316949
Payments from drug & device makers
Across 49 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$210
- Bayer$86
- Indivior Inc.$85
- AstraZeneca$79
- Organon$60
- Lilly USA, LLC$49
- plus $416 from 16 others
What the payments were for
- Food & beverage$985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 9 | $210 |
| Bayer | 5 | $86 |
| Indivior Inc. | 4 | $85 |
| AstraZeneca | 5 | $79 |
| Organon | 1 | $60 |
| Lilly USA, LLC | 3 | $49 |
| AbbVie | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Exact Sciences | 2 | $38 |
| Baxter Healthcare | 1 | $37 |
| Astellas Pharma US Inc | 2 | $37 |
| Tactile Systems Technology Inc | 2 | $37 |
| Novo Nordisk | 2 | $33 |
| Merck | 1 | $23 |
| Corcept Therapeutics | 1 | $20 |
| Viiv Healthcare Company | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Echosens North America, Inc. | 1 | $8 |
How this compares
$985 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 28 | $30,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,831 |
| EliquisApixaban | 15 | $16,402 |
| JardianceEmpagliflozin | 15 | $15,108 |
| JanuviaSitagliptin Phosphate | 14 | $13,419 |
| OzempicSemaglutide | 14 | $13,195 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,459 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,503 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,246 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $3,522 |
| Gabapentin | 50 | $1,093 |
| Bupropion XlBupropion Hcl | 19 | $788 |
| Atorvastatin Calcium | 144 | $740 |
| Omeprazole | 51 | $652 |
| Amlodipine Besylate | 120 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $49 | $30,79528 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $17 | $28,53548 claims |
| MerckJanuvia | $23 | $13,41914 claims |
| Novo NordiskOzempic | $33 | $13,19514 claims |
| AstraZenecaSymbicort | $79 | $4,50315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.
Other family in Mansfield
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.